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Erythrocytosis is defined not only by an increase in the erythrocyte count, hemoglobin concentration, and hematocrit value, but also by 
the occurrence of specific symptoms, the intensity and frequency of which depend on the character of the initial genetic lesion. Ischemic 
episodes and thrombotic complications caused by increased blood viscosity are frequently the first clinical manifestation of the disease. 
This paper represents the current level of knowledge about the pathogenesis of erythrocytosis and the diagnostic algorithms used to 
precisely define the type of the disease.
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Introduction
The term polycythemia was introduced to medical terminology in 1857 
by Denis Jourdanet, on the basis of observation of a consistent increase 
in the viscosity of human blood at high altitudes [1]. Recently, the 
term polycythemia is sometimes replaced by the term erythrocytosis, 
but both terms are not synonymous. The term polycythemia refers to 
any increase in red blood cells, whereas erythrocytosis only refers to 
a documented increase of the red cell mass. An increase in the red 
cell mass is usually associated with the appearance of unspecific 
symptoms like fatigue, headache, dizziness, blurred vision, confusion, 
arthralgia, and skin itching after bathing and exposition to warm 
water. Arterial hypertension and severe burning pain in the hands 
or feet that is usually accompanied by a reddish or bluish coloration 
of the skin and mucosae membranes are also frequently present. 
Thromboembolic disease (TED) episodes are frequently observed in 
subjects with high hematocrit values and erythrocyte count. Recurrent 
nasal bleeding episodes are thus characteristic. The diagnosis of 
erythrocytosis is based on a complete blood count result analysis. 
The absolute erythrocytosis is defined by an increase of the red cell 
mass above 125% of normal value, with hemoglobin concentration and 
hematocrit value >185 and 165 g/L in men and women, respectively. 
The corresponding hematocrit values are 0.52 and 0.48. Abnormal 
hemoglobin and hematocrit values should be confirmed in two 
consecutive measurements to diagnose erythrocytosis [2].
The classification of erythrocytosis includes its primary and secondary 
forms, as well as its inherited and acquired forms (Tab. I).
Despite significant progress in the understanding of the genetic 
background of erythrocytosis, there are still cases with unknown origin. 
In such situations, the term idiopathic erythrocytosis should be used [3].
Hematopoiesis and erythropoiesis regulators
The bone marrow is the primary site of hematopoiesis. In 
normal conditions, hematopoietic stem cells (HSCs) localized in 
microanatomical organizations, termed “niches”, actively interact 
with the bone marrow microenvironment. Recent data suggest that 
hematopoietic progenitor cells differentiation uses different mechanisms 
under steady-state and stress conditions. The proposed mechanism 
of such interaction includes HSCs and progenitor cells interplay with 
growth factors, cytokines, and regulatory factors.
Hematopoiesis is the adaptive process by which mature and functional 
blood cells are continuously replaced over the entire lifetime of an 
individual. As a consequence, the daily production of red blood 
cells, platelets, and neutrophils in homeostatic conditions amounts 
to more than 300 billion cells. The intensity of this process is even 
better illustrated by the observation that an average adult produces 
approximately 2.4 million new red blood cells every second [2].
Erythropoietin (EPO) is the main regulator of red cell production, acting 
on the late erythroid progenitor cells through specific homodimer 
receptor (EPOR) and triggering Janus tyrosine kinase 2 (JAK2) activity, 
with subsequent signal transducer and activator of transcription 5 
(STAT5) phosphorylation and STAT5 dimer formation (JAK2-STAT5 
pathway). Src-homology 2 domain-containing protein tyrosine kinase 1 
(SHP-1) down-regulates the JAK2-STAT5 pathway downstream of 
the EPOR.
It has been postulated that EPO also ensures EPO progenitors survival, 
allowing them to continue the differentiation program initiated mainly by 
GATA-binding factor 1 (GATA-1). The crucial role of EPO in this process 
is evident, because when the EPO level is low, erythroid progenitor 
cells undergo apoptosis upon caspase activation [3]. EPO production 
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in peritubular cells of the kidney is regulated by the oxygen-sensing 
mechanism [4].
The oxygen-sensing pathway
A sensitive mechanism for sensing oxygen and responding to hypoxia 
was identified in humans. It involves a number of proteins. Briefly, 
in normoxic conditions, prolyl hydroxylase domain protein 2 (PHD2) 
hydroxylates one or both elements of a pair of highly conserved 
prolines in hypoxia inducible factor alpha (HIF-2a) in an oxygen-
dependent manner. This hydroxylation enables specific binding of 
HIF-2a by a ubiquitin ligase complex containing von Hippel–Lindau 
(VHL) tumor suppressor, elongin B, and elongin C, which leads 
to its ubiquitination and subsequent proteasomal degradation. 
A little amount of HIF-2a remains to bind the 5′ hypoxia responsible 
element (HRE) of the EPO gene, so the EPO gene transcriptional 
activation is modest. Under hypoxia, the hydroxylation of HIF-2a is 
attenuated, HIF-2a is stabilized, binds to its stable partner – aryl 
hydrocarbon receptor nuclear translocator (ARNT; also known 
as HIF-b), and mediates the transcriptional activation of the EPO 
gene by binding to its HRE and EPO synthesis [4]. The detailed 
mechanism of interaction and activation of target genes in the 
normoxia and hypoxia conditions in the oxygen-sensing pathway is 
presented in detail in figure 1.
Genetic variants responsible for erythrocytosis
The primary erythrocytosis is caused by an intrinsic defect in the bone 
marrow progenitor cells driving the red cell production, and is usually 
characterized by reduced EPO blood concentration. In the secondary 
erythrocytosis, a factor extrinsic to the bone marrow is responsible 
for an increase in the erythroid cells and erythrocyte count. It is 
associated with elevated or normal EPO blood concentration.
Inherited forms of primary erythrocytosis are caused by EPO receptor 
(EPOR) gene mutations. Rarely, the mutations of others genes, like 
SH2B adapter protein 3 (SH2B3, also known as lymphocyte adapter 
protein – LNK), negatively regulating cytokine initiated cell signaling 
by the stem cell factor receptor, thrombopoietin receptor, EPOR, 
platelet-derived growth factor receptor, or the mutations of Janus 
tyrosine kinase 2 (JAK2) gene are responsible for an increase in the 
erythrocyte count [5, 6, 7].
In the secondary erythrocytosis mutations of oxygen-sensing 
pathways, genes [VHL, PHD2 (EGLN1), HIF2A (EPAS1), HBB, 




At least 11 mutations of EPOR gene leading to premature stop codons 
and the loss of SHP-1 docking site are reported. The mutations 
resulted in an abnormal down-regulation of the JAK2-STAT5 pathway 
downstream of the EPOR by SHP-1 and continuous stimulation of the 
red cell production without more EPO [4, 8]. Identified mutations are 
mainly localized in exon 8 of the EPOR gene and concern European 
families only (Tab. II).
Mutations of oxygen-sensing pathways genes
Genetic studies performed in patients’ familial erythrocytosis 
identified a large spectrum of causative mutations in eight candidate 
genes (Tab. II). Their presence can be confirmed in 30%–40% of the 
studied subjects with clinical disease diagnosis [2]. In most of the 
cases, positive family history of erythrocytosis, elevated hemoglobin 
concentration, and/or hematocrit value is found. A detailed analysis 
of laboratory data obtained in patients with PDH2, HIF2a, and EPO 
gene mutation confirms elevated Epo concentration in the blood. Only 
in persons with VHL gene mutations normal Epo blood concentration 
may be found.
In patients carrying the HIF2a mutation, erythrocytosis is observed 
in the late disease phase, and may proceed by symptoms of 
neuroendocrine tumor (glioma, paraglioma). In some patients carrying 
HIF2a gene mutations, only neuroendocrine tumor symptoms 
are present with normal values of hemoglobin concentration and 
erythrocyte count [9]. Hemoglobin oxygen dissociation curve with 
a half-saturation of hemoglobin with oxygen (P50) analysis is 
an important part of the laboratory evaluation of patients with 
Table I. Absolute erythrocytosis classification based on all known causes  [according 2]
Primary erythrocytosis 
(erythroid progenitor defects and hypersentitivity to EPO)
Secondary erythrocytosis 
 (high EPO level and EPO pathway activation)
Acquired Inherited Inherited Acquired
Polycythaemia vera 
- JAK2 V617F mutation 
- ex 12 JAK2 gene 
mutation 
- others mutation
Familial erythrocytosis type 1
- EPOR mutations
High oxygen affinity hemoglobin
- HBB, HBA gene mutation
- BPGM gene mutations
High EPO blood concentration in relation to 
pulmonary disease, cardiac failure, kidney 
disease, liver dysfunction 
Familial erythrocytosis type 3 
- EGLN1 gene mutations
Autonomic EPO production 
(neuroblastoma, renal cancer, 
hepatoma, liver cancer, uterine tumors, 
hemangioblastoma, endocrine tumorsFamilial erythrocytosis type 2
- VHL gene mutations
Familial erythrocytosis type 4 
- EPAS1 mutations
EPO – erythropoietin; EPOR – erythropoietin receptor; HBB – beta globin chain gene; HBA – alpha globin chain gene; VHL – von Hippel-Lindau tumor suppressor gene; EGLN1 – prolyl 
hydroxylase domain 2 gene (previously PDH2); EPAS1 – endothelial PAS domain-containing protein 1 gene (previously HIF2α); BPGM – bisphosphoglycerate mutase gene
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erythrocytosis. Low P50 value suggests the diagnosis of low oxygen 
affinity hemoglobin variant (LOA HGB), bisphosphoglycerate 
mutase gene (BPGM) mutation, or methemoglobinemia (in some 
P50 value is normal). In the case of a normal P50 value, the EGLN1 
(PHD2), EPAS1 (HIF2a), and VHL gene sequencing study should 
be performed. It should be kept in mind that in some patients with 
EGLN1 (rarely EPOR) mutation, the P50 value might be slightly 
decreased. Similarly, in less than 5% of a and b hemoglobin variants 
with high oxygen affinity (HOA HGB), normal or slightly decreased P50 
may be observed. P50 value is normal in patients with erythrocytosis 
and BPGM mutation, as well [9–12].
Congenital erythrocytosis type 1 (ECYT 1; OMIM 133100)
The ECYT1 is primary congenital erythrocytosis and has an autosomal 
dominant inheritance pattern. However, the mutation of exon 8 of the 
Fig. 1. The oxygen-sensing pathway [4, modified]
HIF2α – hypoxia inducible factor 2α; VHL – von Hippel Lindau tumor suppressor protein; HIF-1β – hypoxia inducible factor 1β; EPO – erythropoietin; PHD2 – prolyl hydroxylase domain 2; 
OH – hydroxyl group; HRE – hypoxia response element localized in 5’ flanking region of target genes (i.e. GATA1, ALAS2, Tf and Tfr). HIF binding to HRE resulted in activations of 
transcription of proteins involved in the synthesis of hemoglobin, hem and protein participating in iron absorption from the gastrointestinal tract 
Table II. Gene mutations responsible for inherited erythrocytosis (according to [2, modified]
























BPGM Missense 2,3-BPG 4 Decreased synthesis 
of 2,3-BPG 




















small deletions and 
small insertions
PHD2 30 Loss of function 32 (20 families) Autosomal dominant
EPAS1 Missense HIF2α 12 Gain of function 24 (14 families) Autosomal dominant
HBB – beta globin chain gene; HBA – alfa globin chain gene; EPOR – erythropoietin receptor gene;VHL – von Hippel-Lindau tumour suppressor gene; EGLN1 – prolyl hydroxylase domain 
2 gene; PDH2 – prolyl hydroxylase 2; EPAS1 – endothelial PAS domain-containing protein 1 gene; HIF2α – hypoxia inducible factor 2 alpha; BPGM – bisphosphoglycerate mutase gene
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EPOR gene (chromosome 19p1) may also be found in patients with 
no positive family history of erythrocytosis. The mutations, resulting 
in a loss of the negative regulatory C-terminal domain of the receptor, 
lead to hyperresponsiveness to EPO due to the lack of a negative 
regulation of signal transmission by SHP-1 and suppressor of 
cytokine signaling 3 (SOCS-3). Its presence was described for the 
first time in 1993 in Finnish family members [11, 13] (Tab. III). The 
degree of polycythemia may differ between family members [14]. 
In the majority of cases, the disease is oligosymptomatic. Arterial 
hypertension and history of arterial and venous thrombosis is rarely 
positive. In the symptomatic cases, phlebotomy treatment with the 
normalization of the hematocrit value is needed.
Congenital erythrocytosis type 2 (ECYT 2; OMIM 263400)
The disease was described for the first time in 2002 in Chuvash 
people, inhabitants of the mid-Volga River region (the Chuvash 
polycythemia), and has an autosomal recessive inheritance pattern 
[12]. Chuvash polycythemia was identified in Poland (Acta Haematol. 
Pol. 2020, in press). The VHL gene locus associated with Chuvash 
polycythemia was mapped on chromosome 3p25. In the majority 
of patients, homozygous missense mutation of VHL 598C>T 
(Arg200Trp;R200W) is present. Rarely, the disease is caused by 
combined heterozygous defects. Symptomatic heterozygotes of 
ECYT 2 were also described. Mutation presence resulted in reduced 
degradation of HIF2a and increased expression of downstream 
target genes, including EPO, solute carrier family 2 member 1, 
facilitated glucose transport (SLC2A1), transferrin (TF),  transferrin 
receptor – CD71 (TFRC), and vascular endothelial growth factor 
(VEGF) [12]. The median age of disease diagnosis is 10–19 years 
[15]. The disease is marked by symptoms of increased blood 
volume such as headache, vertigo, or dizziness. Frequent physical 
findings include plethora and a tendency to lower systolic blood 
pressure. Peptic ulcers, angiomas of the spine, and increased 
systolic pulmonary artery pressure are also typical. The Chuvash 
polycythemia carriers are at risk of venous and arterial thrombosis, 
including cerebral vessels, independently from the hematocrit value 
[9, 15]. The propensity to thrombosis is higher than in polycythemia 
vera (PV) [16].
Congenital erythrocytosis type 3 (ECYT 3; OMIM 609820)
Erythrocytosis type 3 causative mutations are identified in Egl nine 
homolog 1 gene (EGLN1). EGLN1 is localized on chromosome 
1q42 and the coding sequence of prolyl hydroxylase 2 (PDH2). 
To date, about 30 mutations have been described in the EGLN1 
gene [17]. The majority of EGLN1 mutations are localized in the 
catalytic domain and impairing binding of HIF-2a/EPAS1. The 
c.950C>G(pro317Arg;P317R) mutation was identified as the first 
one [18].
Congenital erythrocytosis type 4 (ECYT 4; OMIM 611783)
HIF senses and coordinates cellular responses to hypoxia. HIF is 
a heterodimer consisting of one of three alpha (a) subunits 
(expression induced by hypoxia) and a constitutively expressed 
HIFb subunit (also known as aryl hydrocarbon nuclear translocator; 
ARNT). In humans, three paralogs of alpha subunit are known: HIF1a 
(a transcriptional activator and a basic regulator for the expression of 
genes involved in the response to hypoxia), EPAS1 (endothelial PAS 
domain-containing protein 1, also known as HIF2a), and HIF3a [19].
Mutations of the EPAS1 gene (chromosome 2p21) resulted in the 
synthesis of gain of function variants of HIF2a. Until today, a lot of 
missense mutations have been identified in exons 2, 9, 12, and 16 
of the EPAS1 gene [20, 21]. A majority of them are associated with 
amino acid substitution in the proline coding regions of HIF2a(i.e., 
Pro531). An abnormal proline hydroxylation profile resulted in 
impaired recognition of HIF2a by VHL. The final ECYT 4 diagnosis 
should include the EPO blood concentration assessment, which 
is elevated (Fig. 2), and P50 value assessment, which is within the 
normal range. The other two HIFa subunits, HIF1a and HIF3a, have 
been studied as potential factors playing a role in the development of 
erythrocytosis [21].
Congenital erythrocytosis type 5 (ECYT 5; OMIM 617907)
ECYT 5 is associated with a mutation of the EPO gene (chromosome 
7q22). Until today, only seven of the EPO gene variants associated 
with erythrocytosis and an increase in the hematocrit value have 
been identified. They include C306A (upstream), G772T (3′UTR 
enhancer), G136A (5′UTR), exon 2 sequence mutations – C32del 
and c.19delC, p7fs, and mutations of the exon 4 sequence – G84R 
and E99G [13]. Family studies revealed autosomal dominant trait of 
inheritance. In 10 members of a four-generation Norwegian family, 
a single nucleotide deletion in exon 2 of the EPO gene within the 
signal peptide sequence was found (c.32delG; OMIM 133170.0002) 
[22–25].
Congenital erythrocytosis types 6–8 (ECYT 6–8)
Beta chain hemoglobin gene mutations (HBB) are responsible for 
the congenital erythrocytosis type ECYT 6 (OMIM 617980) and 
Table III. Indications for erythrocytophoresis in patients with 
erythrocytosis [46]
Erythrocytosis 











1Level of evidence: 1A – strong recommendation, high-quality evidence; 1B – strong 
recommendation, moderate-quality evidence; 1C – strong recommendation, low or very 
low-quality evidence; 2A – weak recommendation, high-quality evidence; 2B – weak 
recommendation, moderate-quality evidence; 2C – weak recommendation, low or very low-
quality evidence. 2Indication category: I – disorders for which apheresis is accepted as first-
line therapy, either as a primary standalone treatment or in conjunction with other modes of 
treatment; II – disorders for which apheresis is accepted as second-line therapy, either as a 
standalone treatment or in conjunction with other modes of treatment; III – optimum role of 
apheresis therapy is not established. Decision making should be individualized
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result in the HOA HGB variant. Disease diagnosis is possible on the 
basis of the P50 evaluation and a sequencing study of the HBB gene 
localized on chr11q15. A similar laboratory characteristic is typical 
for ECYT 7 (OMIM 617981), caused by alpha chain hemoglobin 
gene mutations (HBA), and for ECYT 8 (OMIM 222800), associated 
with the bisphosphoglycerate mutase deficiency due to BPGM gene 
mutations. The above-mentioned gene aberrations are localized on 
chromosomal regions 16p13 and 7q33, respectively.
The diagnostic algorithm of congenital absolute erythrocytosis is 
presented in figure 2. The laboratory consequences of mutations of 
the genes of the oxygen-sensing pathway (PHD2-HIF-vHL-EPO) are 
presented in table II.
Erythrocytosis and thrombotic risk
The increase of hemoglobin, hematocrit value, and erythrocyte 
count may lead to the rise of venous and arterial thrombotic risk. 
The results of a study performed in Sweden among 1.5 million blood 
donors revealed a 2.4 times higher risk of an ischemic cerebral stroke 
in both males and females with the hemoglobin value above 17.5 and 
16.0 g/dL, respectively. The risk evaluation included the country of 
origin, age, season of the year, the time from the last blood donation, 
and the existence of other comorbidities, including pulmonary 
obstructive disease, cancer, diabetes, atrial fibrillation, nocturnal 
dyspnea, and coronary artery disease. A similar relationship was 
documented in terms of the increase of the relative risk of TED in 
men with elevated hemoglobin levels above 17.5 g/dL (lower limbs 
thrombosis, pulmonary embolism – 1.5x) [26].
The risk of TED was also studied in familial erythrocytosis caused 
by genetic variants responsible for erythrocytosis. In the analysis 
performed by Gordeuk et al. [27] in a six-generation family carrying 
c.1603A>G (M535V), mutation of the EPAS1 (HIF2a) gene showed 
that thrombotic episodes were observed even in the young family 
members treated with phlebotomy in whom the hematocrit value was 
kept below 45%.
PV (Vaquez disease) is a clonal disorder of the HSC. In 95% of 
patients, the V617F mutation (exon 14) of the JAK2 gene localized 
on chr 9p24.1 is present in the coding sequence of the JAK2 
pseudokinase domain (JH2). The amino acid substitution resulted in 
an abnormal JH2 inhibitory effect on the adjacent JH1 kinase domain, 
thus keeping JAK2 in an inactive conformation [28]. In another 3% of 
patients, mutations of the JAK2 gene are present in exon 12 (until 
now, 37 molecular aberrations different in nature were described – 
synonymous substitutions, deletion variants, duplications) [29]. PV 
is a rare disease with an annual incidence of 1.5/100,000 people 
from the general population [26]. Morbidity is estimated at 0.49–
46.88/100,000 people/year. The 5-year overall survival is estimated 
at 88.4% [30]. The diagnostic criteria proposed in 2016 by WHO 
include an increase in the hemoglobin level above the value of 16 g/dL 
in females and 16.5 g/dL in males; an increase in the hematocrit 
value above 48% and 49%, respectively, and total erythrocytes 
mass. The diagnostic criteria also include bone marrow hyperplasia, 
the presence of a JAK2 clonal aberration in the hematopoietic cells 
(JAK2 V617F or exon 12 mutation) and subnormal EPO blood 
concentration. EPO blood concentration is closely associated with 
the presence of a JAK2 gene mutation (normal EPO concentration is 
present only in 32% of JAK2 mutation carriers). The relationship of 
the EPO level and the driving defect presence is especially evident 
in the case of exon 12 JAK2 mutations (subnormal EPPO level is 
present in 91% of patients) [31, 32].
The symptoms of PV are associated with an increased blood volume 
and hyperviscosity and include vertigo, transient ischemic attacks, 
cardiac ischemia, and TED episodes. A laboratory evaluation of 
PV patients revealed high hemoglobin and hematocrit values, 
leukocytosis, and thrombocythosis. The fibrosis of the bone marrow 
and symptoms of metaplasia with the presence of erythroblasts and 
unmaturated neutrophils in peripheral blood film are also observed 
in the late disease phase. In some cases, thrombocytosis is 
a dominant laboratory abnormality, which may suggest the diagnosis 
of essential thrombocythemia (masked PV) [33]. A disease evolution 











HBB, HBA gene sequencing
BPGM gene sequencing
Mutation(s)









EPAS1 gene ex12 sequencing








Normal, subnormal + other symptoms
of MPN  (ANC and or PLT)
JAK2 V617F
(if negative ex12 sequencing)
Fig. 2. Algorithm for the laboratory evaluation of erythrocytosis [2, 3; modified] 
ECYT – erythrocytosis; HBB – hemoglobin beta chain gene; HBA – hemoglobin alpha chain gene; EPOR – erythropoietin receptor gene; VHL – von Hippel-Lindau tumor suppressor gene; 
EGLN1 – prolyl hydroxylase domain 2 gene; EPAS1 – endothelial PAS domain-containing protein 1 gene; BPGM – bisphosphoglycerate mutase gene; P50 – half saturation of hemoglobin 
with oxygen; MPN – myeloproliferative neoplasm; JAK2 – Janus kinase 2 gene; ANC – absolute neutrophil count; PLT – platelets; ex – exon 
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is typical with a possible transformation to secondary acute myeloid 
leukemia with the frequency of 2.3%–14.4% at 10 years and 5.5%–
18.7% at 15 years from the initial diagnosis [34]. The JAK2 variant 
allele frequency (VAF) increases during this time, as well. The latter 
phenomenon is closely associated with an increase of the thrombotic 
risk [35]. The study by Barbui et al. [36] performed in patients with PV 
confirmed that 15 years after the diagnosis, 32% of cases experienced 
arterial and venous thromboembolic complications. Despite the 
progress in the thrombotic risk stratification and modification of the 
prophylactic algorithms used, the thrombotic events remain the main 
cause of mortality and morbidity in patients with PV [37–40].
In Chuvash erythrocytosis the risk of thrombotic episodes occurrence 
is relatively high. On the basis of data by Sergueeva et al. [16], the 
propensity to thrombosis of people with Chuvash erythrocytosis is 
even higher than in PV patients. The thrombotic risk assessment in 
other types of erythrocytosis is difficult to calculate due to the relatively 
low disease incidence and lack of cumulative data. A detailed 
analysis of the available data indicates that thrombosis accounts 
for the morbidity and mortality of Chuvash erythrocytosis patients, 
independently from body mass index, systemic blood pressure, 
serum glucose and glycosylated hemoglobin level, white cell, and 
platelet count [41, 42]. The frequency of thrombotic complications is 
high even in children and adolescents with Chuvash polycythemia 
and high hematocrit value, independently of age, which is not 
a predictor of thrombotic risk [15]. Moreover, therapeutic phlebothomy 
seems to increase the thrombotic risk in Chuvash erythrocytosis [16]. 
This is probably the result of hypoxia-induced prothrombotic state 
associated with a reduced tissue pathway inhibitor (TFPI) mRNA and 
protein level, increased tissue factor (TF) mRNA expression [43], the 
upregulation of tissue factor expression [44], and the expression of 
thrombospondin-1 (THBS-1 gene) [16]. It cannot be excluded that 
the thrombotic risk is also affected by hypoxia-induced reduction of 
protein S expression [45].
Phlebotomy and cytoreductive treatment of 
erythrocytosis
Phlebotomy (erythrocytopheresis) is the standard of care of patients 
with an elevated hemoglobin level, red cell mass, and hematocrit 
value. Phlebotomy is efficient in the treatment of symptoms 
associated with high hematocrit value. Its efficacy in the reduction of 
thrombotic risk in patients with erythrocytosis remains to be clarified 
[46]. Two prospective randomized studies (PVSG 01 and PVSG 
05) demonstrated that phlebotomy used to control hematocrit was 
associated with a higher thrombotic risk compared to chemotherapy 
[47, 48]. The higher rate of thrombosis related to bloodletting was 
also evident when phlebotomy was performed in patients receiving 
aspirin and dipyridamole treatment (PVSG 05 comparing the clinical 
efficacy of phlebotomy in combination with aspirin and dipyridamole 
vs. 32P). In the opinion of the study investigators, the increased 
thrombotic risk in the phlebotomy treated patients in comparison 
to the subjects obtaining myelosuppressive therapy (chlorambucil, 
32P) seems to be limited to the first 3 years of the treatment 
[47, 49]. An advantage of cytoreductive therapy with hydroxyurea 
(HU) over phlebotomy in terms of fatal/non-fatal cardiovascular events 
incidence was documented by the European Collaboration on Low-
Dose Aspirin in the Polycythemia Vera (ECLAP) study (3.0 vs. 5.8 per 
100 person-years, respectively) on the basis of a clinical evaluation 
of 1,042 patients with PV [50]. The impact of hematocrit value on 
the thrombosis risk in PV patients was studied by the Cytoreductive 
Therapy in Polycythemia Vera (CYTO-PV) Collaborative Group. 
The study confirmed high thrombotic risk in patients with a high 
hematocrit value, regardless of whether the patient was treated with 
chemotherapy and whether the white blood cell count was elevated 
[51].
The other problem studied was the relationship between the 
frequency of therapeutic phlebotomies and the thrombotic risk. An 
observational study performed by Alvarez-Larran et al. [52] confirmed 
a correlation between the number of phlebotomies and an increased 
incidence of thrombosis in the HU-treated patients. The existence of 
such association was not confirmed by Barbui et al. [53].
Recently, the factors influencing the risk of thrombosis in PV patients 
have been re-evaluated and new scoring systems for more adequate 
risk stratification have been prepared. One of them is the scale for 
thrombosis risk assessment, including only two separate categories: 
high risk (either thrombosis history or advanced age >60 years) and 
low risk (the absence of both risk factors) with the consideration of 
arterial hypertension and leukocytosis as additional risk factors in 
certain circumstances [54]
Janus kinase 2 inhibitors in the treatment of PV
A randomized study result published in 2015 by Vannucchi et al. 
[55], comparing the best available therapy versus ruxolitinib (RUX) 
in hydroxyurea-resistant or intolerant PV with splenomegaly, showed 
higher rates of hematocrit control in RUX arm (60% vs. 20%), ≥35% 
reduction in the spleen volume (38% vs. 1%), and symptom control 
(49% vs. 5%). Unfortunately, the study was not designed to address 
clinically relevant endpoints in PV, such as the thrombosis rate 
and thrombosis-free survival. The thrombotic risk was re-analyzed 
recently, due to the introduction of JAK2 inhibitors to the treatment 
of PV patients. The data originating from four randomized clinical 
studies (RESPONSE, RESPONSE-2, RELIEF, MAJIC-PV) including 
1,216 patients showed the annual frequency of thrombotic episodes 
at 4.3%. The thrombotic risk was higher in patients treated with BAT 
than with RUX (5.51% vs. 3.09%) [56].
The thrombosis risk reduction is probably associated with the anti-
cytokine effect of JAK2 inhibitors. Chronic inflammatory state as 
a result of paracrine secretion of inflammatory cytokines by neoplastic 
cells is present in patients with myeloproliferative neoplasms [57, 58].
Interferon in the treatment of PV
Interferon alfa has the capacity to selectively reduce the malignant 
JAK2 mutated stem cell clone content [59, 60, 61]. Recently, 
Gisslinger et al., on the basis of phase 3, randomized, controlled open-
label studies (PROUD-PV and its extension study, CONTINUATION-
PV), documented that in patients with early PV phase without 
splenomegaly, pegylated interferon alfa 2b (PEG-interferon alfa 2b) 
was as effective as hydroxyurea after 12 months of treatment in terms 
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of complete hematological responses (non-inferior vs. HU). However, 
in contrast to HU, the PEG-interferon 2b treatment continuation 
up 36 months was associated with higher response rates and with 
a higher proportion of patients with molecular response (a steady 
decrease in the mean absolute JAK2 V617F allele burden level by 
month 36 from 42.8% at baseline to 19.7%). The corresponding 
ratios in the HU treated group was 42.9% at baseline to 39.3% at 
month 36. Due to good tolerability of PEG interferon 2b treatment and 
relatively high hematological and molecular response ratios, the study 
investigators recommend starting the treatment with PEG-interferon 
2b in the early disease phase to prevent disease clonal evolution [62].
Conclusions
Recently, a British Society for Hematology guideline for the 
management of specific situations in PV and secondary erythrocytosis 
was published [63]. Unfortunately, only the recommendations 
concerning the treatment of clinical complications in PV are strong 
and are supported by high-quality evidences. The recommendations 
concerning the management of secondary erythrocytosis are 
still a matter of debate and have weak recommendations based 
on the moderate or even low- or very low-quality evidences. It is 
a consequence of the lack of the data concerning the patients with 
a specific molecularly proven diagnosis of secondary erythrocytosis. 
Therefore, there is a need to collect available data about the clinical 
outcome and treatments results in patients with inherited, specific 
forms of erythrocytosis in order to prepare the standards of care.
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